The European Aids Clinical Society guideline (not yet adjusted to the new nomenclature) recommends screening for NAFLD in PHIV with obesity, metabolic syndrome, persistent ALT elevation, and exposure to d-drugs [44]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.